CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates a senolytic drug cocktail that targets senescent cells to reduce the side effects of cancer chemotherapy. The treatment aims to enhance the effectiveness of chemotherapy while minimizing harmful impacts on non-cancerous tissues.
Many of the clinically used cancer chemotherapies have considerable short-term side effects, including fatigue, bone marrow suppression, nausea, diarrhea, and hair loss.
Long-term side effects include cognitive impairment, organ dysfunction, and even secondary cancers. A body of evidence indicates that senescent cells induced by chemotherapy in non-cancerous tissues play a major part in these toxicities of chemotherapy.
As part of the SENCAN grant, we have developed a cocktail of two drugs that…
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
